# Oncolytic Virus in Esophageal Squamous Cell Carcinoma

> **NCT07061704** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sichuan University** · enrollment: 40 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **BIOLOGICAL:** Oncolytic Virus: Administered via intratumoral injection (metastatic lesions in the neck or supraclavicular lymph nodes) once every 3 weeks, for a total of two to four doses.
- **BIOLOGICAL:** Oncolytic Virus: Administered via intratumoral injection (primary lesions) once every 3 weeks, for a total of two to four doses.

## Key facts

- **NCT ID:** NCT07061704
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07061704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07061704, "Oncolytic Virus in Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07061704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*